Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2019

31 May - 4 Jun 2019

McCormick Place, Chicago, United States of America

Implementing national cancer control plans

Dr Eduardo Cazap and Dr Lisa Stevens

Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )

Comment: POLO III trial for metastatic pancreatic cancer

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: POLO III trial for metastatic pancreatic cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Getting high level care to low and middle income countries

Dr Eduardo Cazap, Dr Clifford Hudis

Getting high level care to low and middle income countries ( Dr Eduardo Cazap, Dr Clifford Hudis )

Tackling the increase in cancer cases worldwide

Dr Eduardo Cazap and Prof Tezer Kutluk

Tackling the increase in cancer cases worldwide ( Dr Eduardo Cazap and Prof Tezer Kutluk )

How will ASCO combat cancer disparities?

Dr Eduardo Cazap, Dr Richard Schilsky

How will ASCO combat cancer disparities? ( Dr Eduardo Cazap, Dr Richard Schilsky )

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Are PARP inhibitors a new standard of care option for MBC patients?

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

Are PARP inhibitors a new standard of care option for MBC patients? ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

The potential of PARP inhibitors in new cancer groups and in combination with...

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Dr Joel Neal - Stanford University, Stanford, USA

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )

Comment: Enfortumab vedotin is an effective therapy and important development...

Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )

Cancer care in low and middle income countries

Dr Gouri Shankar Bhattacharyya - FORTIS Hospital, Kolkata, India

Cancer care in low and middle income countries ( Dr Gouri Shankar Bhattacharyya - FORTIS Hospital, Kolkata, India )

Cancer care in Latin America

Dr Jean Rene Clemenceau - Hospital Angeles del Pedregal, Mexico City, Mexico

Cancer care in Latin America ( Dr Jean Rene Clemenceau - Hospital Angeles del Pedregal, Mexico City, Mexico )

Surveying cancer patients' mental health and financial problems

Dr Daniel Vorobiof - Sandton Oncology Centre, Sandton, South Africa

Surveying cancer patients' mental health and financial problems ( Dr Daniel Vorobiof - Sandton Oncology Centre, Sandton, South Africa )

Implementing better cancer diagnosis in low and middle income countries

Dr Gilberto Lopes - University of Miami and the Miller School of Medicine...

Implementing better cancer diagnosis in low and middle income countries ( Dr Gilberto Lopes - University of Miami and the Miller School of Medicine, Miami, USA )

Project Pink Blue: Fighting cancer through increasing awareness, screening...

Runcie C.W. Chidebe - Executive Director, Project PINK BLUE

Project Pink Blue: Fighting cancer through increasing awareness, screening, advocacy and patient navigation ( Runcie C.W. Chidebe - Executive Director, Project PINK BLUE )

Challenges in global cancer control

Prof Mary Gospodarowicz - University Health Network, Toronto, Canada

Challenges in global cancer control ( Prof Mary Gospodarowicz - University Health Network, Toronto, Canada )

Novel methods of drug testing and biopsy in India

Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India

Novel methods of drug testing and biopsy in India ( Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India )

Cutting-edge cancer care at the Miami Cancer Institute

Dr Miguel Villalona - Miami Cancer Institute, Miami, USA

Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo...

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

NILE: Should we give everything to patients with unresectable locally advanced...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer? ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Comment: Chemotherapy for frail and elderly patients with advanced...

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: Chemotherapy for frail and elderly patients with advanced gastroesophageal cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Comment: Laparoscopic versus open resection for colorectal liver metastases

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: Laparoscopic versus open resection for colorectal liver metastases ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

CheckMate-142: Updated data from MSI high metastatic colon cancer patients ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA...

Prof Hope Rugo - University of California, San Francisco, USA

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Advances in PARP inhibitor use for metastatic breast cancer

Prof Hope Rugo - University of California, San Francisco, USA

Advances in PARP inhibitor use for metastatic breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Margetuximab for the treatment of HER2-positive breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Margetuximab for the treatment of HER2-positive breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

The future of PARP inhibitors in metastatic breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

The future of PARP inhibitors in metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced...

Dr Tira Tan - National Cancer Centre, Singapore

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer ( Dr Tira Tan - National Cancer Centre, Singapore )

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in...

Dr Johannes Ettl - Technical University, Munich, Germany

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer ( Dr Johannes Ettl - Technical University, Munich, Germany )

ECHO palliative care in Africa: Improving access to quality palliative care

Runcie C.W. Chidebe - Executive Director, Project PINK BLUE

ECHO palliative care in Africa: Improving access to quality palliative care ( Runcie C.W. Chidebe - Executive Director, Project PINK BLUE )

Developments in neoadjuvant immunotherapy options for early-stage lung cancer...

Dr Luis Raez - Memorial Healthcare System, Hollywood, USA

Developments in neoadjuvant immunotherapy options for early-stage lung cancer patients ( Dr Luis Raez - Memorial Healthcare System, Hollywood, USA )

Implementing the Breast Health Global Initiative guidelines

Prof Benjamin Anderson - Fred Hutchinson Cancer Center, Seattle, USA

Implementing the Breast Health Global Initiative guidelines ( Prof Benjamin Anderson - Fred Hutchinson Cancer Center, Seattle, USA )

A phase II study of bemcentinib with pembrolizumab in patients with advanced...

Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Expanding clinical trial eligibility criteria: Risks and solutions

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Ribociclib plus endocrine therapy improves survival in premenopausal patients...

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

ASCO 2019 and vision for cancer control

Dr Eduardo Cazap - Editor-in-Chief, ecancer

ASCO 2019 and vision for cancer control ( Dr Eduardo Cazap - Editor-in-Chief, ecancer )

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland...

Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial ( Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA )

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2...

Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer ( Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA )

Guiding treatment decisions through the use of molecular profiling in breast...

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Guiding treatment decisions through the use of molecular profiling in breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Managing metastatic breast cancer and beyond using PARP inhibitors

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Updates in metastatic and early-stage breast cancer

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors in metastatic breast cancer: Where are we now?

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus...

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor...

Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies ( Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands )

VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG...

Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany

VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )

SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant...

Prof Thomas Flaig - University of Colorado Denver, Denver, USA

SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer ( Prof Thomas Flaig - University of Colorado Denver, Denver, USA )

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive...

Prof Hope Rugo - University of California, San Francisco, USA

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies ( Prof Hope Rugo - University of California, San Francisco, USA )

Updates in the management of pancreatic cancer from ASCO 2019

Dr Ian Chau, Prof Michel Ducreux and Dr Vaihab Sahai

Updates in the management of pancreatic cancer from ASCO 2019 ( Dr Ian Chau, Prof Michel Ducreux and Dr Vaihab Sahai )

Genetic testing and PARP inhibitors in metastatic prostate cancer

Dr Neal Shore and Dr Joaquin Mateo

Genetic testing and PARP inhibitors in metastatic prostate cancer ( Dr Neal Shore and Dr Joaquin Mateo )

Metastatic castration resistant prostate cancer: Updates from ASCO 2019

Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi

Metastatic castration resistant prostate cancer: Updates from ASCO 2019 ( Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi )

Preliminary results of earlier steroid use with axicabtagene ciloleucel in...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE)...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

POLO Trial: Olaparib as a maintenance treatment following first-line...

Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona...

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer ( Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )

Breast cancer highlights from ASCO 2019

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until...

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

$Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )$

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )

Proton therapy or photon therapy as part of concurrent chemoradiotherapy for...

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA

Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )

Carfilzomib and irinotecan in relapsed small cell lung cancer

Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA

Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )

FORTE trial results: KRd with or without transplantation in newly diagnosed...

Dr Francesca Gay - University Hospital City of Health and Science of Turin...

FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma according to risk status ( Dr Francesca Gay - University Hospital City of Health and Science of Turin, Turin, Italy )

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast...

Dr Zahi Mitri - OHSU Hospital, Portland, USA

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in...

Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcomas ( Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA )

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients...

Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )

ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

$ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )$

Prostate cancer updates: TITAN and ENZAMET

Prof Ian Davis and Prof Axel Merseburger

Prostate cancer updates: TITAN and ENZAMET ( Prof Ian Davis and Prof Axel Merseburger )

Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019

Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger

Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019 ( Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger )

Metastatic bladder cancer: Current practice and latest data from ASCO 2019

Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones

Metastatic bladder cancer: Current practice and latest data from ASCO 2019 ( Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones )

Highlights from ASCO 2019

Asst. Prof Bishal Gyawali and Monique Biryiana

Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )

Potential of PARP inhibitors for metastatic breast cancer

Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA

Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )

Preventing brain metastases in patients with HER2 or triple negative breast...

Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA

Preventing brain metastases in patients with HER2 or triple negative breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )

Understanding eligibility criteria for clinical trials to increase study size

Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills...

Understanding eligibility criteria for clinical trials to increase study size ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )

Long-term survival after laparoscopic versus open resection for colorectal...

Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway

Long-term survival after laparoscopic versus open resection for colorectal liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )

Targeting agent enfortumab vedotin a novel treatment for patients with advanced...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

Expanded clinical trial inclusion criteria would double the percentage of...

Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills...

Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )

New agent targeting Nectin-4 produces responses in nearly half of patients with...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

No difference in survival between laparoscopic surgery and open surgery in...

Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway

No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )

Novel therapies in the treatment of bladder cancer

Dr Petros Grivas and Dr Andrea Necchi

Novel therapies in the treatment of bladder cancer ( Dr Petros Grivas and Dr Andrea Necchi )

Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer...

Prof Arnaud Mejean - Paris Descartes University, Paris, France

Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population ( Prof Arnaud Mejean - Paris Descartes University, Paris, France )

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA...

Dr Hedy Kindler - University of Chicago, Chicago, USA

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Enzalutamide as treatment for men with mHSPC who have received testosterone...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Enzalutamide improves survival for men with metastatic hormone-sensitive...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Comment: Using enzalutamide will allow patients to avoid chemotherapy and...

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA

Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA )

Maintenance therapy with PARP inhibitor olaparib delays progression in patients...

Dr Hedy Kindler - University of Chicago, Chicago, USA

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Comment: It is essential to identify the BRCA gene in pancreatic cancer...

Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent ( Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA )

Improving cancer care outcomes in Ghana through mentorship

Dr Verna Vanderpuye - Korle Bu Teaching Hospital, Accra, Ghana

Improving cancer care outcomes in Ghana through mentorship ( Dr Verna Vanderpuye - Korle Bu Teaching Hospital, Accra, Ghana )

Clinical and translational results from the NEOSTAR study: Treating early-stage...

Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston...

Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti...

Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients ( Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany )

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors are a promising alternative to chemotherapy for patients with...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Subcutaneous versus intravenous daratumumab administration in patients with...

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

$Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )$

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as...

Dr Edward B. Garon - UCLA, Los Angeles, USA

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal...

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona...

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )

Comment: Reasonable to conclude that pembrolizumab is non-inferior to...

Dr Richard Schilsky and Dr Josep Tabernero

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or...

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona...

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )

Comment: The success of immunotherapy means we have to change our mindset as we...

Dr David Graham and Dr Edward B. Garon

Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )

Pembrolizumab is safe and effective and substantially increases overall...

Dr Edward B. Garon - UCLA, Los Angeles, USA

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients ( Dr Edward B. Garon - UCLA, Los Angeles, USA )

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival...

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Ribociclib and endocrine therapy improves survival for pre-menopausal women...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

More from ecancer